{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:57:01Z","timestamp":1792213021467,"version":"4.4.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.phrs.2019.104567","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T11:19:24Z","timestamp":1574507964000},"page":"104567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"special_numbering":"C","title":["The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder"],"prefix":"10.1016","volume":"151","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104567_bib0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.phrs.2019.104567_bib0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2019.104567_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"10.1016\/j.phrs.2019.104567_bib0020","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2019.104567_bib0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.molcel.2006.01.022","article-title":"Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction","volume":"21","author":"Furdui","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2019.104567_bib0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2019.104567_bib0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature25451","article-title":"\u03b1-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling","volume":"553","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.104567_bib0040","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104567_bib0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tibs.2012.12.001","article-title":"KIDs rule: regulatory phosphorylation of RTKs","volume":"38","author":"Locascio","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2019.104567_bib0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104567_bib0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104567_bib0060","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0065","first-page":"197","article-title":"Kinase-centric computational drug development","volume":"50","author":"Kooistra","year":"2017","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0070","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104567_bib0075","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0080","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0085","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2019.104567_bib0090","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1021\/ja312237q","article-title":"Phosphoryl transfer by protein kinase A is captured in a crystal lattice","volume":"135","author":"Bastidas","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2019.104567_bib0095","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1039\/C7MT00204A","article-title":"Divalent metal ions control activity and inhibition of protein kinases","volume":"9","author":"Knape","year":"2017","journal-title":"Metallomics"},{"key":"10.1016\/j.phrs.2019.104567_bib0100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","article-title":"A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases","volume":"27","author":"Chen","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2019.104567_bib0105","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104567_bib0110","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104567_bib0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2019.104567_bib0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0155","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0160","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0165","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0185","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0205","doi-asserted-by":"crossref","first-page":"e1001690","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2019.104567_bib0210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0220","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2019.104567_bib0225","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.phrs.2019.104567_bib0230","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918788310","article-title":"Approved checkpoint inhibitors in bladder cancer: which drug should be used when?","volume":"10","author":"Ghatalia","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phrs.2019.104567_bib0235","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1358\/dot.2019.55.8.3010573","article-title":"Erdafitinib to treat urothelial carcinoma","volume":"55","author":"Hanna","year":"2019","journal-title":"Drugs Today (Barc.)"},{"key":"10.1016\/j.phrs.2019.104567_bib0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0245","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2019.104567_bib0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semcdb.2015.10.012","article-title":"Dysregulated FGF signalling in neoplastic disorders","volume":"53","author":"Tanner","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2019.104567_bib0255","doi-asserted-by":"crossref","first-page":"24252","DOI":"10.18632\/oncotarget.8132","article-title":"Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use","volume":"7","author":"Patani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2019.104567_bib0260","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2019.104567_bib0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104567_bib0270","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/10428190600822128","article-title":"Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma","volume":"47","author":"Keats","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2019.104567_bib0275","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2019.104567_bib0280","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2019.104567_bib0285","first-page":"41","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0290","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2019.104567_bib0295","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/acs.bioconjchem.6b00243","article-title":"Bivalent inhibitors of c-Src tyrosine kinase that bind a regulatory domain","volume":"27","author":"Johnson","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0305","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2015.18","article-title":"The drug-target residence time model: a 10-year retrospective","volume":"15","author":"Copeland","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.104567_bib0310","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0315","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2019.104567_bib0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2019.104567_bib0325","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2019.104567_bib0330","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104567_bib0335","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2019.104567_bib0340","doi-asserted-by":"crossref","first-page":"F351","DOI":"10.1152\/ajprenal.00232.2013","article-title":"Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4","volume":"306","author":"Gattineni","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.phrs.2019.104567_bib0345","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant fibroblast growth factor 19 signaling as a driver event in hepatocellular carcinoma","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.phrs.2019.104567_bib0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147845","article-title":"Conditional deletion of Fgfr1 in the proximal and distal tubule identifies distinct roles in phosphate and calcium transport","volume":"11","author":"Han","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104567_bib0355","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","author":"Facchinetti","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0360","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0365","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.10.002","article-title":"Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel","volume":"120","author":"M\u00fcller","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2019.104567_bib0370","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104567_bib0375","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.phrs.2019.104567_bib0380","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","article-title":"Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4","volume":"22","author":"Tucker","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.phrs.2019.104567_bib0385","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.jmb.2014.09.004","article-title":"Structural analysis of the human fibroblast growth factor receptor 4 kinase","volume":"426","author":"Lesca","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2019.104567_bib0390","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1021\/cb500674s","article-title":"DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors","volume":"10","author":"Huang","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2019.104567_bib0395","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ebiom.2015.02.009","article-title":"The effect of mutations on drug sensitivity and kinase activity of fibroblast growth factor receptors: a combined experimental and theoretical study","volume":"2","author":"Bunney","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2019.104567_bib0400","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1038\/ncomms8877","article-title":"Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase","volume":"6","author":"Klein","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2019.104567_bib0405","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.5b00014","article-title":"Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles\u2019 heel of targeted therapy","volume":"10","author":"Sohl","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2019.104567_bib0410","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification","volume":"28","author":"Van Cutsem","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2019.104567_bib0415","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284\/Debio 1347, a novel selective FGFR inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2019.104567_bib0420","doi-asserted-by":"crossref","first-page":"10586","DOI":"10.1021\/acs.jmedchem.6b01156","article-title":"Discovery of [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284\/Debio 1347), an orally available and selective fibroblast growth factor receptor (FGFR) inhibitor","volume":"59","author":"Ebiike","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0425","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0430","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104567_bib0435","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-91442-8_13","article-title":"Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR\u03b1, KIT and RET","volume":"211","author":"Zsch\u00e4bitz","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0440","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.phrs.2019.104567_bib0445","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cam4.1517","article-title":"Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models","volume":"7","author":"Matsuki","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.phrs.2019.104567_bib0450","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2019.104567_bib0455","doi-asserted-by":"crossref","first-page":"e0162491","DOI":"10.1371\/journal.pone.0162491","article-title":"Crystal structure of the FGFR4\/LY2874455 complex reveals insights into the pan-FGFR selectivity of LY2874455","volume":"11","author":"Wu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104567_bib0460","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","article-title":"A phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer","volume":"12","author":"Michael","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.phrs.2019.104567_bib0465","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/j.1582-4934.2012.01541.x","article-title":"AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR","volume":"16","author":"Zhou","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2019.104567_bib0470","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2019.104567_bib0475","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2019.104567_bib0480","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-18-1291","article-title":"FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of FGF19-driven hepatocellular cancer","author":"Weiss","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2019.104567_bib0485","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1039\/C9CC02052G","article-title":"Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4","volume":"55","author":"Zhou","year":"2019","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.phrs.2019.104567_bib0490","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","article-title":"H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma","volume":"77","author":"Joshi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0495","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1021\/jm900431g","article-title":"Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)","volume":"52","author":"Roth","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0500","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1074\/jbc.RA119.007682","article-title":"Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib","volume":"294","author":"Terzyan","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0505","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0510","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.celrep.2017.10.076","article-title":"High-throughput drug screening identifies pazopanib and clofilium tosylate as promising treatments for malignant rhabdoid tumors","volume":"21","author":"Chauvin","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2019.104567_bib0515","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2019.104567_bib0520","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cmdc.201700718","article-title":"Discovery of rogaratinib (BAY 1163877): a pan-FGFR inhibitor","volume":"13","author":"Collin","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2019.104567_bib0525","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.104567_bib0530","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","author":"Hatlen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2019.104567_bib0535","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1021\/acs.jmedchem.7b00360","article-title":"Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors","volume":"60","author":"Brameld","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104567_bib0540","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0545","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MOP.0b013e32833b7a69","article-title":"Achondroplasia: pathogenesis and implications for future treatment","volume":"22","author":"Laederich","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.phrs.2019.104567_bib0550","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng0395-321","article-title":"Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3","volume":"9","author":"Tavormina","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2019.104567_bib0555","doi-asserted-by":"crossref","DOI":"10.1007\/s00381-019-04244-7","article-title":"Pfeiffer type 2 syndrome: review with updates on its genetics and molecular biology","author":"Rai","year":"2019","journal-title":"Childs Nerv. Syst."},{"key":"10.1016\/j.phrs.2019.104567_bib0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0565","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2019.104567_bib0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","author":"Kanev","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2019.104567_bib0575","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2019.104567_bib0580","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0585","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.phrs.2016.03.024","article-title":"Blocking the FGF\/FGFR system as a \"two-compartment\" antiangiogenic\/antitumor approach in cancer therapy","volume":"107","author":"Giacomini","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.104567_bib0590","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819326398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819326398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:06:30Z","timestamp":1760911590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819326398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":118,"alternative-id":["S1043661819326398"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104567","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104567"}}